<

INVENTIVA (EPA:IVA) Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

Transparency directive : regulatory news

21/10/2024 14:30

source : webdisclosure.com



Other stories

26/12/2024 13:46
26/12/2024 11:33
26/12/2024 13:55
26/12/2024 13:13
26/12/2024 11:41
26/12/2024 11:42
26/12/2024 11:42
26/12/2024 12:08
26/12/2024 10:53
26/12/2024 10:34
25/12/2024 19:46
25/12/2024 20:42
24/12/2024 19:33
25/12/2024 23:06
26/12/2024 11:06
26/12/2024 06:00
26/12/2024 09:27
26/12/2024 01:01
26/12/2024 03:12
26/12/2024 07:21
25/12/2024 08:03
25/12/2024 09:55
26/12/2024 10:20
26/12/2024 09:25
26/12/2024 10:07
26/12/2024 07:00
26/12/2024 13:16
26/12/2024 11:25
26/12/2024 12:25
26/12/2024 14:05
26/12/2024 13:30
24/12/2024 16:30
24/12/2024 15:56
26/12/2024 13:00
26/12/2024 00:56
26/12/2024 08:00
26/12/2024 10:50
25/12/2024 06:00